JP2019513370A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513370A5
JP2019513370A5 JP2018551953A JP2018551953A JP2019513370A5 JP 2019513370 A5 JP2019513370 A5 JP 2019513370A5 JP 2018551953 A JP2018551953 A JP 2018551953A JP 2018551953 A JP2018551953 A JP 2018551953A JP 2019513370 A5 JP2019513370 A5 JP 2019513370A5
Authority
JP
Japan
Prior art keywords
seq
region
amino acid
acid sequence
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018551953A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513370A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/025573 external-priority patent/WO2017173384A1/en
Publication of JP2019513370A publication Critical patent/JP2019513370A/ja
Publication of JP2019513370A5 publication Critical patent/JP2019513370A5/ja
Pending legal-status Critical Current

Links

JP2018551953A 2016-04-01 2017-03-31 キメラ受容体及びその使用方法 Pending JP2019513370A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317068P 2016-04-01 2016-04-01
US62/317,068 2016-04-01
PCT/US2017/025573 WO2017173384A1 (en) 2016-04-01 2017-03-31 Chimeric receptors and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020152515A Division JP7134204B2 (ja) 2016-04-01 2020-09-11 キメラ受容体及びその使用方法

Publications (2)

Publication Number Publication Date
JP2019513370A JP2019513370A (ja) 2019-05-30
JP2019513370A5 true JP2019513370A5 (https=) 2019-10-24

Family

ID=59960746

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018551953A Pending JP2019513370A (ja) 2016-04-01 2017-03-31 キメラ受容体及びその使用方法
JP2020152515A Active JP7134204B2 (ja) 2016-04-01 2020-09-11 キメラ受容体及びその使用方法
JP2022136417A Active JP7451627B2 (ja) 2016-04-01 2022-08-30 キメラ受容体及びその使用方法
JP2024033511A Active JP7673272B2 (ja) 2016-04-01 2024-03-06 キメラ受容体及びその使用方法
JP2025071243A Pending JP2025111619A (ja) 2016-04-01 2025-04-23 キメラ受容体及びその使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020152515A Active JP7134204B2 (ja) 2016-04-01 2020-09-11 キメラ受容体及びその使用方法
JP2022136417A Active JP7451627B2 (ja) 2016-04-01 2022-08-30 キメラ受容体及びその使用方法
JP2024033511A Active JP7673272B2 (ja) 2016-04-01 2024-03-06 キメラ受容体及びその使用方法
JP2025071243A Pending JP2025111619A (ja) 2016-04-01 2025-04-23 キメラ受容体及びその使用方法

Country Status (33)

Country Link
US (3) US10597456B2 (https=)
EP (2) EP4180449A1 (https=)
JP (5) JP2019513370A (https=)
KR (7) KR102731644B1 (https=)
CN (3) CN113150170B (https=)
AR (1) AR108066A1 (https=)
AU (3) AU2017240788B2 (https=)
BR (1) BR112018070260A2 (https=)
CA (2) CA3019650C (https=)
CL (5) CL2018002797A1 (https=)
CO (1) CO2018010547A2 (https=)
CR (2) CR20210084A (https=)
DK (1) DK3436030T3 (https=)
EA (1) EA201891992A1 (https=)
ES (1) ES2930058T3 (https=)
HR (1) HRP20221348T1 (https=)
HU (1) HUE060645T2 (https=)
IL (2) IL262041B2 (https=)
LT (1) LT3436030T (https=)
MA (1) MA43603A1 (https=)
MX (2) MX2018012019A (https=)
MY (1) MY197669A (https=)
PE (3) PE20211418A1 (https=)
PH (1) PH12018502113A1 (https=)
PL (1) PL3436030T3 (https=)
PT (1) PT3436030T (https=)
RS (1) RS63735B1 (https=)
SG (2) SG10201912519VA (https=)
SI (1) SI3436030T1 (https=)
SM (1) SMT202200444T1 (https=)
TW (5) TWI855499B (https=)
UA (2) UA123276C2 (https=)
WO (1) WO2017173384A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
BR112018069601A2 (pt) 2016-03-31 2019-01-29 Janssen Pharmaceuticals Inc derivados de indolina substituídos como inibidores da replicação viral da dengue
BR112018068676A2 (pt) 2016-03-31 2019-01-15 Janssen Pharmaceuticals Inc derivados de indol substituídos como inibidores da replicação viral do dengue
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA3019650C (en) 2016-04-01 2023-07-25 Kite Pharma, Inc. Chimeric receptors and methods of use thereof
TWI795133B (zh) 2016-04-01 2023-03-01 美商凱特製藥公司 Bcma結合分子類及彼等之用途
ES2891578T3 (es) * 2016-04-01 2022-01-28 Kite Pharma Inc Antígeno quimérico y receptores de células T y métodos de uso
BR112018068956A2 (pt) 2016-04-01 2019-01-22 Janssen Pharmaceuticals Inc derivados do composto indol substituídos como inibidores da replicação viral da dengue
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
UA125970C2 (uk) 2017-05-22 2022-07-20 Янссен Фармасьютікалз, Інк. Заміщені похідні індоліну як інгібітори реплікації вірусів денге
EP3630723B1 (en) 2017-05-22 2022-08-24 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
EP3710471A1 (en) 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
KR102439221B1 (ko) 2017-12-14 2022-09-01 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
CN109609533B (zh) * 2017-12-27 2020-07-10 赛德特生物科技开发有限公司 基于人源化cd276抗体的car慢病毒表达载体构建及其应用
US12473336B2 (en) 2018-02-21 2025-11-18 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses thereof
KR20210046006A (ko) * 2018-08-10 2021-04-27 상가모 테라퓨틱스 프랑스 Tnfr2 도메인을 포함하는 신규한 car 작제물
JP2022505921A (ja) * 2018-10-26 2022-01-14 カファ セラピューティクス リミテッド Cll1を標的とする抗体およびその応用
PH12021551720A1 (en) 2019-03-01 2022-03-28 Allogene Therapeutics Inc Dll3 targeting chimeric antigen receptors and binding agents
EP3966236A4 (en) * 2019-05-07 2023-05-10 The Board of Trustees of the Leland Stanford Junior University Enhancement of polypeptides and chimeric antigen receptors via hinge domains
SG11202111943UA (en) 2019-07-02 2021-11-29 Hutchinson Fred Cancer Res Recombinant ad35 vectors and related gene therapy improvements
AU2020346887A1 (en) * 2019-09-13 2022-04-07 Memorial Hospital For Cancer And Allied Diseases Antigen recognizing receptors targeting CD371 and uses thereof
CN112500492B (zh) * 2019-09-13 2023-08-04 中国科学院分子细胞科学卓越创新中心 一种嵌合抗原受体及其用途
CN113045658B (zh) 2020-12-11 2021-12-24 广州百暨基因科技有限公司 抗cll1抗体及其应用
CN113234169B (zh) * 2020-12-11 2022-11-01 广州百暨基因科技有限公司 靶向cll1嵌合抗原受体及其应用
CN113234162B (zh) * 2020-12-24 2022-05-13 四川大学华西医院 一种靶向cd133的嵌合抗原受体t细胞
CN113416713A (zh) * 2021-05-11 2021-09-21 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) 一种重组腺病毒的构建及其应用
CN115521917A (zh) * 2021-06-25 2022-12-27 南京北恒生物科技有限公司 工程化免疫细胞及其用途
US20250101104A1 (en) 2022-01-26 2025-03-27 Mabswitch Inc. Bispecific molecule with tunable affinity to a targeted antigen
TW202340457A (zh) * 2022-02-28 2023-10-16 美商凱特製藥公司 同種異體治療細胞
US20240091261A1 (en) 2022-08-26 2024-03-21 Kite Pharma, Inc. Immune cell function
GB202214132D0 (en) 2022-09-27 2022-11-09 Coding Bio Ltd CLL1 binding molecules
GB202301949D0 (en) 2023-02-10 2023-03-29 Coding Bio Ltd CLL1 and/or CD33 binding molecules
US20240293462A1 (en) * 2023-03-03 2024-09-05 Trustees Of Boston University Immune Cell Fusion (ICF) and Uses Thereof
WO2024218688A1 (en) * 2023-04-18 2024-10-24 Board Of Regents, The University Of Texas System Bcma chimeric antigen receptors and uses thereof
WO2025194098A1 (en) 2024-03-14 2025-09-18 Dana-Farber Cancer Institute, Inc. Engineered immune cells expressing chimeric antigen receptors targeting trop2, and methods of using the same
WO2025231376A1 (en) * 2024-05-03 2025-11-06 Kite Pharma, Inc. Chimeric receptors binding to cll-1 and methods of use thereof

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US20030036654A1 (en) 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6892139B2 (en) 1999-01-29 2005-05-10 The Regents Of The University Of California Determining the functions and interactions of proteins by comparative analysis
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7393531B2 (en) 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
EP2322547A1 (en) * 2003-06-25 2011-05-18 Crucell Holland B.V. Myeloid cell-specific lectin
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7794890B2 (en) 2004-09-03 2010-09-14 Gm Global Technology Operations, Inc. Aligning method for repeating and non-repeating units in a fuel cell stack
WO2007137300A2 (en) 2006-05-23 2007-11-29 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
US8536310B2 (en) * 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
DK2352756T3 (da) 2008-11-24 2012-12-03 Helmholtz Zentrum Muenchen Højaffin T-cellereceptor og anvendelse af denne
MX341884B (es) 2009-03-10 2016-09-07 Biogen Ma Inc Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
CA2776143A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
US20120227134A1 (en) 2009-11-17 2012-09-06 Basf Plant Science Company Gmbh Plants with Increased Yield
EP2566886A1 (en) 2010-05-05 2013-03-13 Addex Pharma SA Methods and tools for screening agents exhibiting an activity on receptors of the tumor necrosis factor receptor superfamily
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
ES2602743T3 (es) 2010-09-08 2017-02-22 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Receptores de antígenos quiméricos con una región bisagra optimizada
WO2012033885A1 (en) 2010-09-08 2012-03-15 Baylor College Of Medicine Immunotherapy of cancer using genetically engineered gd2-specific t cells
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR20140004174A (ko) 2011-01-18 2014-01-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 치료를 위한 조성물 및 방법
AU2012209103B2 (en) 2011-01-26 2015-12-03 Takeda Pharmaceutical Company Limited Methods and compositions for the synthesis of multimerizing agents
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
KR101972446B1 (ko) 2011-05-27 2019-04-25 글락소 그룹 리미티드 Bcma(cd269/tnfrsf17)­결합 단백질
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
CN103946952A (zh) 2011-09-16 2014-07-23 宾夕法尼亚大学董事会 用于治疗癌症的rna改造的t细胞
DE102012204596A1 (de) 2012-03-22 2013-09-26 Ford Global Technologies, Llc Verfahren und Vorrichtung zum Regeln der Geschwindigkeit eines Kraftfahrzeugs
EP2828290B1 (en) 2012-03-23 2018-08-15 The United States of America, represented by the Secretary, Department of Health and Human Services Anti-mesothelin chimeric antigen receptors
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
RU2766608C2 (ru) 2012-04-11 2022-03-15 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
US9163090B2 (en) * 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
WO2014122143A1 (en) 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
CN113005091A (zh) 2013-02-06 2021-06-22 细胞基因公司 具有改进特异性的修饰的t淋巴细胞
DK2956175T3 (da) 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
EP3925618A1 (en) 2013-07-29 2021-12-22 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
EP3074419B1 (en) 2013-11-25 2018-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors to control hiv infection
WO2015080981A1 (en) 2013-11-27 2015-06-04 Baylor College Of Medicine Csgp4-specific chimeric antigen receptor for cancer
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
AU2015214145A1 (en) 2014-02-04 2016-08-25 Kite Pharma. Inc. Methods for producing autologous T cells useful to treat B cell malignancies and other cancers and compositions thereof
US10934346B2 (en) 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
US20170335281A1 (en) * 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
EP3131927B8 (en) 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
SG10201913782UA (en) * 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
ES2878449T3 (es) 2014-07-24 2021-11-18 2Seventy Bio Inc Receptores antigénicos quiméricos de BCMA
JP2017529841A (ja) 2014-09-19 2017-10-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. キメラ抗原受容体
BR112017005631A2 (pt) 2014-09-19 2018-06-26 City Of Hope células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2
KR102558502B1 (ko) 2014-12-05 2023-07-20 시티 오브 호프 Cs1 표적화된 키메라 항원 수용체-변형된 t 세포
HRP20191873T1 (hr) 2014-12-12 2020-01-24 Bluebird Bio, Inc. Kimerni antigenski receptori
TWI703159B (zh) 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma特異性治療性抗體及其用途
US10294304B2 (en) 2015-04-13 2019-05-21 Pfizer Inc. Chimeric antigen receptors targeting B-cell maturation antigen
TWI795133B (zh) 2016-04-01 2023-03-01 美商凱特製藥公司 Bcma結合分子類及彼等之用途
ES2891578T3 (es) 2016-04-01 2022-01-28 Kite Pharma Inc Antígeno quimérico y receptores de células T y métodos de uso
CA3019650C (en) 2016-04-01 2023-07-25 Kite Pharma, Inc. Chimeric receptors and methods of use thereof
IL262061B2 (en) 2016-04-01 2023-03-01 Amgen Inc Chimeric flt-3 receptors and methods of using them

Similar Documents

Publication Publication Date Title
JP2019513370A5 (https=)
AU2019243665B2 (en) Multivalent antibody
CN111018986B (zh) 抗磷脂酰肌醇蛋白多糖-3的抗体及其应用
JP2022550832A (ja) Cd3を標的とする抗体、二重特異性抗体及びその使用
CA3116294C (en) Anti-l1cam antibody or antigen-binding fragment thereof and chimeric antigen receptor comprising same
WO2018108106A1 (zh) 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞
JP2020508655A5 (https=)
FI4063397T3 (fi) Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi
JP2022504802A5 (https=)
CN112028996A (zh) 靶向bcma的单域抗体及其用途
RU2018107802A (ru) Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин
JP2018522888A5 (https=)
JP2016536322A5 (https=)
JP2022542559A5 (https=)
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
JP2018528786A5 (https=)
KR20230143177A (ko) 신규한 항-cd24 항체
JP2024001073A5 (https=)
IL316226A (en) Anti-ror1 antibody and ror1-targeting engineered cells
JP2022529380A5 (https=)
JP2024105603A (ja) CARライブラリおよびscFvの製造方法
AU2020400801B2 (en) Anti-BCMA/anti-4-1BB bispecific antibodies and uses thereof
JP2024541476A5 (https=)
JP2021529539A5 (https=)
KR20210046725A (ko) 신규 암 면역요법 항체 조성물